Executive SummaryFDA approved the beta blocker for use in treatment of angina. In press material announcing the approval, Stuart said Tenormin "is more selective" than the other two beta-blockers approved for angina (Corgard and Inderal) -- "meaning that it has more effect on beta than beta receptors -- which may result in fewer side effects for certain patients".
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.